Zürcher Kantonalbank's Disclosure on Avadel Pharmaceuticals

Zürcher Kantonalbank has released a Form 8.3 disclosure regarding its position in Avadel Pharmaceuticals plc. This form pertains to the Irish Takeover Panel Act of 1997 and relates to interests in relevant securities representing 1% or more. The disclosure uses the latest practical data dated January 14, 2026.

The bank and its subsidiaries hold 37,707 ordinary shares of Avadel Pharmaceuticals, accounting for 0.04% of the relevant securities. This disclosure does not include any cash or stock-settled derivative activities or transactions applicable to other parties involved in an offer.

No additional agreements, inducements, or understandings pertaining to indemnity or options were reported, indicating standard disclosure under Rule 8.3 without supplemental documentation. No Supplemental Form 8 is attached.